A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Head of Pharmacovigilance Operations Vice President - Head of Pharmacovigilance Operations, Innovation & Analytics

Biology & BiotechPosted on Nov 10
Full-time$289k - $391k

About the Job

Requirements

  • A bachelor's degree in a scientific or healthcare field and at least 20 years of relevant work experience in a global pharmacovigilance or related operational biotechnology/pharmaceutical role are required.
  • Progressive experience serving in a management role with remit including pharmacovigilance, risk management, and quality-related matters is required.
  • Experience leading compliance or audits and working knowledge of relevant FDA, EU, and ICH guidelines, Good Pharmacovigilance Practice regulations, safety reporting and processing for clinical-trial environments, and regulatory quality aspects are required.
  • Ability to design and operationalize governance models, decision-making frameworks, escalation pathways, and pharmacovigilance compliance and performance-management processes is required.
  • Demonstrated success in organizational transformation and operating-model design and implementation is required.
  • Significant experience managing strategic partnerships, contract research organizations, and external service providers, including vendor governance, performance management, and contract oversight, is required.
  • Strong financial and business acumen, including experience partnering with Finance on forecasting, budgeting, investment planning, and scenario modeling, is required.
  • Experience developing executive-level insights, dashboards, and performance metrics to support informed decision-making and organizational transparency is required.
  • Strategic thinking and problem-solving capabilities, including anticipating risks, evaluating trade-offs, and driving operational excellence, are required.
  • Excellent communication and executive presence, including the ability to synthesize complex information into clear, actionable recommendations, are required.
  • Demonstrated ability to lead organizational change, build scalable operating models, and drive continuous-improvement initiatives is required.
  • The candidate must demonstrate alignment with Alnylam's core values: commitment to people, innovation and discovery, sense of urgency, open culture, and passion for excellence.

Responsibilities

  • Define, govern, and scale the operating model that enables Safety & Risk Management and Regulatory Sciences to execute pharmacovigilance across clinical development and marketed products.
  • Own integrated planning architecture, governance frameworks, resource and capacity strategy, external-partner performance, delivery-performance insights, and a large budget supporting global pharmacovigilance regulatory duties.
  • Lead all operational aspects of the Safety and Risk Management Expertise Area, including pharmacovigilance reporting compliance, safety-information case management, scientific knowledge building, process innovation and implementation, and business-partner/vendor management.
  • Build and lead high-performing Pharmacovigilance Operations, Innovation & Analytics teams, providing strategic oversight and financial soundness.
  • Provide strategic leadership and oversight of process design, evaluation, and review of all Safety and Risk Management procedures, pharmacovigilance operational innovation, and operational excellence.
  • Foster partnerships with Commercial and Medical Affairs, Clinical Operations, Quality Assurance, Data Management, IT, Finance, and external partners.
  • Partner with Quality Assurance to manage audits and inspections effectively and promote a successful pharmacovigilance Quality Management System.
  • Ensure relevant standard operating procedures, systems, and processes are in place for an efficient and compliant Safety & Risk Management organization.
  • Provide strategic consultation and guidance to development and commercial/Medical Affairs Expertise Areas on decisions with significant pharmacovigilance operational implications, including postmarketing-study safety reporting, market-research activities, and Patient Access programs such as Alnylam Assist.
  • Oversee tracking of key performance indicators for reporting-compliance metrics related to Safety & Risk Management and Regulatory Quality activities.
  • Provide strategic leadership and input into system requirements and process design for pharmacovigilance operations and analytics, collaborating with IT to ensure efficient, high-quality pharmacovigilance systems, including Argus, PVReports, and Empirica.
  • Partner with the Qualified Person Responsible for Pharmacovigilance to provide strategic direction and quality and compliance leadership to Safety & Risk Management.
  • Define and execute the pharmacovigilance vendor strategy, ensuring governance, accountability, and partnerships that support speed, quality, cost efficiency, and enterprise objectives.
  • Provide strategic leadership and performance management of external partners, including case-management and medical-review vendors and clinical-trial safety-reporting vendors across trials.
  • Drive vendor strategy, governance frameworks, and accountability mechanisms to ensure high-quality, cost-effective delivery aligned with safety-reporting regulations, obligation timelines, and organizational priorities.
  • Lead governance of case-management, medical-review, and other partner relationships, focusing on value realization and risk mitigation.
  • Advise senior leaders on operating-model design, systems strategy, and execution effectiveness.
  • Champion collaboration, transparency, accountability, and innovation.
  • Develop organizational capabilities that enable the company to scale and deliver development and commercial pharmacovigilance activities.

Desired Qualifications

  • An MD degree or other senior degree is highly preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs